These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30887420)

  • 21. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors.
    Janisch F; Klotzbücher T; Marks P; Kienapfel C; Meyer CP; Yu H; Fühner C; Hillemacher T; Mori K; Mostafei H; Shariat SF; Fisch M; Dahlem R; Rink M
    World J Urol; 2021 Aug; 39(8):2977-2985. PubMed ID: 33649869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma.
    Zhang F; Xie Y; Ma X; Gu L; Li H; Li X; Guo G; Zhang X
    Urol Oncol; 2019 Mar; 37(3):184.e9-184.e17. PubMed ID: 30509867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.
    Soerensen AV; Geertsen PF; Christensen IJ; Hermann GG; Jensen NV; Fode K; Petersen A; Sandin R; Donskov F
    Acta Oncol; 2016; 55(3):341-8. PubMed ID: 26449266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mast cell density in metastatic renal cell carcinoma: Association with prognosis and tumour-infiltrating lymphocytes.
    Yao J; Xi W; Chen X; Xiong Y; Zhu Y; Wang H; Hu X; Guo J
    Scand J Immunol; 2021 Apr; 93(4):e13006. PubMed ID: 33275792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    Iacovelli R; Lanoy E; Albiges L; Escudier B
    BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
    Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
    Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Liu Y; Zhou L; Chen Y; Liao B; Ye D; Wang K; Li H
    BMC Urol; 2019 Jun; 19(1):49. PubMed ID: 31174518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
    Haaker L; Tryssesoone L; Renders I; Verbiest A; Lerut E; Baldewijns M; Bourgain C; Roussel E; Van den Bulck H; Wynendaele W; Laguerre B; Rioux-Leclercq N; Oudard S; Laenen A; Debruyne PR; Albersen M; Beuselinck B
    Urol Oncol; 2020 Aug; 38(8):686.e1-686.e9. PubMed ID: 32430250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
    Pilskog M; Beisland C; Akslen LA; Bostad L; Haug Å; Heinrich D; Hjelle KM; Straume O
    BMC Urol; 2017 Aug; 17(1):74. PubMed ID: 28859644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; de Cobelli O; Nolè F
    Anticancer Drugs; 2017 Feb; 28(2):206-212. PubMed ID: 27754995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
    Poprach A; Pavlik T; Melichar B; Kubackova K; Bortlicek Z; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Buchler T;
    Urol Oncol; 2014 May; 32(4):488-95. PubMed ID: 24321257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
    Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
    BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
    Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
    Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Wells JC; Graham J; Beuselinck B; Bjarnason GA; Donskov F; Hansen AR; McKay RR; Vaishampayan U; De Velasco G; Duh MS; Huynh L; Nguyen C; Zanotti G; Ramaswamy K; Choueiri TK; Heng DYC
    Clin Genitourin Cancer; 2020 Aug; 18(4):e350-e359. PubMed ID: 31926879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
    Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.